Infection and Drug Resistance (Jul 2021)
Combination Therapy of Polymyxin B and Amikacin for Community-Acquired Pseudomonas aeruginosa Pneumonia with MODS in a Previously Healthy Patient: A Case Report
Abstract
Junyu Wang,1 Lu Yun,1 Hong Zhao,1 Xiangpeng Li2 1Department of Pharmacy, Qingdao Central Hospital, Qingdao, 266042, Shandong, People’s Republic of China; 2Department of Pharmacy, The Affiliated Hospital of Qingdao University, Qingdao, 266003, Shandong, People’s Republic of ChinaCorrespondence: Xiangpeng LiDepartment of Pharmacy, The Affiliated Hospital of Qingdao University, 16 Jiangsu Road, Shinan District, Qingdao, 266003, Shandong, People’s Republic of ChinaTel +86-532-82912182; +86-18661809083Email [email protected]: Pseudomonas aeruginosa (P. aeruginosa) is an uncommon but fatal causative pathogen for community-acquired pneumonia (CAP). Few case reports described the previously healthy individuals with CAP caused by P. aeruginosa.Case Presentation: A 67-year-old male farmer was referred to our hospital with a 6-day history of fever and shortness of breath. The radiologic findings revealed a dense consolidation site in the right lung, considering infection lesion, accompanying with mediastinal and right hilar lymphadenopathy. Sputum sample results showed P. aeruginosa and multidrug-resistant Acinetobacter baumannii. The combination of polymyxin B and amikacin was given to him based on the lab results, the manifestations of the patient were alleviated and he returned to his home after a 35-day hospitalization.Conclusion: We need to keep close attention to community-acquired P. aeruginosa pneumonia due to its high mortality, further studies are needed to identify the infectious source, effective examination, and optimal therapy including medications and duration.Keywords: Pseudomonas aeruginosa, community-acquired pneumonia, polymyxin B and amikacin, a case report